A method for determining the presence or absence of at least one cancer-associated super-enhancer in a primary cancerous biological sample obtained from a subject relative to a matched primary non-cancerous biological sample, wherein the primary cancerous biological sample is gastric cancer, comprising; a) contacting the primary cancerous biological sample obtained from the subject with at least one antibody specific for histone modification H3K27ac; b) isolating nucleic acid from the primary cancerous biological sample, wherein the isolated nucleic acid comprises at least one region specific to the histone modification H3K27ac, wherein the nucleic acid is isolated from the cancerous biological sample by immunoprecipitation of chromatin specific to the histone modification H3K27ac; c) mapping at least one enhancer using an annotated genome sequence based on a signal intensity of the histone modification H3K27ac, wherein the at least one enhancer is at least 2.5 kb from an annotated transcription start site; d) mapping the at least one enhancer in the isolated nucleic acid against at least one enhancer in at least one reference nucleic acid sequence to identify at least one cancer-associated super-enhancer in the primary cancerous biological sample; e) comparing the signal intensity of the at least one cancer-associated super-enhancer in the primary cancerous biological sample against a reference signal intensity of the at least one cancer-associated super-enhancer obtained from the matched primary non-cancerous biological sample, wherein the signal intensity of the at least one cancer-associated super-enhancer is based on the Reads Per Kilobase of transcript per Million (RPKM) value of the histone modification H3K27ac; and f) determining the presence or absence of the at least one cancer-associated super-enhancer in the primary cancerous biological sample based on the change in signal intensity of the at least one cancer-associated super-enhancer, comprising determining that the RPKM value for the at least one cancer-associated super-enhancer in the primary cancerous biological sample is: i) greater than a 2-fold change in RPKM value relative to the RPKM value of the at least one cancer-associated super-enhancer obtained from the matched primary non-cancerous biological sample; and ii) an absolute difference greater than a 0.5 RPKM relative to the RPKM value of the at least one cancer-associated super-enhancer obtained from the matched primary non-cancerous biological sample. a) contacting the primary cancerous biological sample obtained from the subject with at least one antibody specific for histone modification H3K27ac; b) isolating nucleic acid from the primary cancerous biological sample, wherein the isolated nucleic acid comprises at least one region specific to the histone modification H3K27ac, wherein the nucleic acid is isolated from the cancerous biological sample by immunoprecipitation of chromatin specific to the histone modification H3K27ac; c) mapping at least one enhancer using an annotated genome sequence based on a signal intensity of the histone modification H3K27ac, wherein the at least one enhancer is at least 2.5 kb from an annotated transcription start site; d) mapping the at least one enhancer in the isolated nucleic acid against at least one enhancer in at least one reference nucleic acid sequence to identify at least one cancer-associated super-enhancer in the primary cancerous biological sample; e) comparing the signal intensity of the at least one cancer-associated super-enhancer in the primary cancerous biological sample against a reference signal intensity of the at least one cancer-associated super-enhancer obtained from the matched primary non-cancerous biological sample, wherein the signal intensity of the at least one cancer-associated super-enhancer is based on the Reads Per Kilobase of transcript per Million (RPKM) value of the histone modification H3K27ac; and f) determining the presence or absence of the at least one cancer-associated super-enhancer in the primary cancerous biological sample based on the change in signal intensity of the at least one cancer-associated super-enhancer, comprising determining that the RPKM value for the at least one cancer-associated super-enhancer in the primary cancerous biological sample is: i) greater than a 2-fold change in RPKM value relative to the RPKM value of the at least one cancer-associated super-enhancer obtained from the matched primary non-cancerous biological sample; and ii) an absolute difference greater than a 0.5 RPKM relative to the RPKM value of the at least one cancer-associated super-enhancer obtained from the matched primary non-cancerous biological sample. i) greater than a 2-fold change in RPKM value relative to the RPKM value of the at least one cancer-associated super-enhancer obtained from the matched primary non-cancerous biological sample; and ii) an absolute difference greater than a 0.5 RPKM relative to the RPKM value of the at least one cancer-associated super-enhancer obtained from the matched primary non-cancerous biological sample.